Merck & Co., Inc. MRK

Merck & Co., Inc. es una empresa global de atención médica. La compañía ofrece soluciones de salud a través de sus medicamentos con receta, vacunas, terapias biológicas y productos de salud animal. Opera a través de dos segmentos: Farmacéutico y Salud Animal. El segmento Farmacéutico de la compañía incluye productos farmacéuticos y vacunas para la salud humana. Sus productos farmacéuticos para la salud humana consisten en agentes terapéuticos y preventivos, generalmente vendidos con receta, para el tratamiento de trastornos humanos. La compañía vende estos productos farmacéuticos para la salud humana principalmente a mayoristas de medicamentos y minoristas, hospitales, agencias gubernamentales y proveedores de atención médica gestionada como organizaciones de mantenimiento de la salud. El segmento de Salud Animal desarrolla, fabrica y comercializa una amplia gama de productos farmacéuticos y vacunas veterinarias, así como soluciones y servicios de gestión de la salud, para la prevención, tratamiento y control de enfermedades en todas las principales especies de ganado y animales de compañía.

Con 7 acciones de MRK (USD 1.005,52) habrías recibido USD 23,80 en dividendos en los últimos 12 meses.

• GlobeNewswire Inc. 2 oct

  Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

  Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.

  

• Zacks Investment Research 1 oct

  Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

  Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications.

  

• Zacks Investment Research 1 oct

  ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?

  AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026.

  

• Zacks Investment Research 30 sept

  Why Merck (MRK) Dipped More Than Broader Market Today

  Merck (MRK) declined 2.66% to $145.31, underperforming the S&P 500. The pharmaceutical company's upcoming Q3 2026 earnings are expected on October 29, with projected EPS of $2.25 (down 12.79% YoY) and revenue of $17.52 billion (up 1.39% YoY). The stock carries a Zacks Rank #3 (Hold) with a Forward P/E of 53.99, significantly above the industry average of 16.43.

  

• The Motley Fool 30 sept

  Prediction: Moderna Stock Will Soar 100% by 2030

  Moderna has rebounded from pandemic-era lows with a diversified product portfolio including COVID, RSV, and flu vaccines, plus promising oncology pipeline candidates. The analyst predicts 100% stock appreciation by 2030 based on potential revenue growth to ~$3 billion and positive pipeline data, though acknowledges manufacturing challenges for personalized cancer vaccines and current high valuation multiples.